Epitopea Ltd
Drug Discovery
- Website
- https://www.epitopea.com/
- Membership category
- Corporate
Milner Therapeutic Inst, Cambridge University, Cambridge, CB2 0AH, United Kingdom
Epitopea Ltd at a glance
Revealing the real targets for next generation immunotherapies.
About Epitopea Ltd
Epitopea is a newly established trans-Atlantic cancer immunotherapeutics company developing therapeutics to target a novel class of tumour specific antigens (TSAs). Jointly headquartered in Montreal (QC) and Cambridge (UK), the company closed its Seed Round financing in December, 2021 from a transatlantic syndicate of top-tier investors including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, and the Fonds de solidarité FTQ.
Epitopea’s mission is to create transformational off-the-shelf immunotherapies to treat solid tumours and haematological malignancies based on actionable sets of aberrantly-expressed TSAs (cryptigensTM). The company has an exclusive license from Université de Montréal to an extensive IP estate covering cryptigen identification methodology, plus sets of cryptigens for multiple indications with considerable unmet need.
Epitopea’s initial platform is based on the innovative proteogenomic approach to immunopeptidomics pioneered by Claude Perreault and Pierre Thibault at Université de Montréal. Cryptigens represents a new class of shared actionable TSAs that may be targeted by a wide variety of therapeutic modalities including therapeutic vaccines, TCR-T cells and TCR- or antibody-based bi-specifics.